Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction
Academic Article
Publication Date:
2020
Abstract:
Two pharmaceutical agents have been approved for treatment of idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib.
CRIS type:
1.1 Articolo in rivista
Keywords:
Body mass index; Idiopathic pulmonary fibrosis; Nintedanib; Therapy
List of contributors:
Harari, Sergio; Specchia, Claudia; Lipsi, Roberto; Cassandro, Roberto; Caminati, Antonella
Published in: